We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First-Ever Blood Test Diagnoses Maternal Autoantibody Related Autism

By LabMedica International staff writers
Posted on 10 Oct 2024
Print article
Image: The simple blood test will identify the likelihood of a woman having a child with autism (Photo courtesy of 123RF)
Image: The simple blood test will identify the likelihood of a woman having a child with autism (Photo courtesy of 123RF)

Maternal Autoantibody Related Autism (MARA) is a subtype of autism linked to the presence of specific autoantibodies in a mother. The identification of MARA marks a significant breakthrough in the early, even pre-symptomatic, detection of autism in children. MARA has been associated with more severe forms of autism and is estimated to account for about 20% of all autism cases. Now, a groundbreaking blood test can accurately determine whether a woman carries the autoantibodies responsible for MARA. This test can be used to diagnose MARA in children at birth or even predict its likelihood before pregnancy.

MARAbio Systems (Salt Lake City, UT, USA) has created precision technology capable of predicting a child's likelihood of having MARA through a simple maternal blood test, even before symptoms emerge or before pregnancy. The MARAbio test measures up to eight specific autoantibodies, and their combinations, that are linked to a form of autism affecting nearly 20% of diagnosed cases. This test allows for the detection of the MARA subtype of autism in a child before symptom onset and can also aid in diagnosing MARA in children with developmental delays. Additionally, it can be used by women at higher risk before pregnancy to assess their likelihood of having a child with MARA-related autism.

The MARAbio test offers the potential to accelerate the diagnosis of autism and the initiation of therapy for children born to mothers who test positive. Early behavioral intervention is known to improve the quality of life for individuals with autism, and identifying the MARA subtype may enable therapists to customize intervention strategies for better outcomes. The test can also be useful for pre-pregnancy screening in high-risk women and may support the development of therapeutic approaches to reduce the risk of having a child with MARA.

Related Links:
MARAbio Systems

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more